ARS Pharmaceuticals price to book ratio SPRY

Market value divided by the book value of the company's net assets, since 2021.

Today, Oct 23, 2026: 32.0×
5-year median: 3.1×
Against its 5-year history: 96th; percentile: 0 is its lowest day, 100 its highest
5-year range: 0.3× to 46.8×
Peer median: 1.9×

ARS Pharmaceuticals' price to book ratio is 32.0× as of Oct 23, 2026.

That is above its 5-year median of 3.1×, higher than on 96% of days in the last 5 years.

Over that time it ranged from 0.3× in May 2022 to 46.8× in Aug 2026.

The median for 10 large drugmakers of a similar size is 1.9×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	32.0×	5.9×	46.8×
2025	7.6×	4.5×	7.8×
2024	5.2×	2.3×	7.7×
2023	2.2×	0.9×	3.1×
2022	1.2×	0.3×	1.2×
2021	0.7×	0.7×	3.1×

Against its peers

Companies in Drug Manufacturers - General nearest ARS Pharmaceuticals' size, closest first, today.

Company	Price to book ratio
SPRYARS Pharmaceuticals	32.0×
ARVNArvinas	0.8×
PBYIPuma Biotechnology	4.1×
IRWDIronwood Pharmaceuticals	n/m
ZVRAZevra Therapeutics	2.7×
CRMDCorMedix	1.3×
COLLCollegium Pharmaceutical	2.4×
NATRNatures Sunshine Products	1.3×
ABUSArbutus Biopharma	3.2×
AMPHAmphastar Pharmaceuticals	1.4×
OMEROmeros	n/m
Peer median	1.9×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on ARS Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.